Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. See package insert for complete information.

CYLTEZO is a tumor necrosis factor (TNF) blocker indicated for:
•Rheumatoid Arthritis (RA).
•Juvenile Idiopathic Arthritis (JIA)
•Psoriatic Arthritis (PsA)
•Ankylosing Spondylitis (AS)
•Crohn’s Disease (CD)
•Ulcerative Colitis (UC)
•Plaque Psoriasis (Ps)

Injection: 40 mg/0.8 mL and 20 mg/0.4 mL in single-dose prefilled glass syringe.

Most common adverse reactions (>10%) are: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.

None.

Serious infections: Do not start CYLTEZO during an active infection. If an infection develops, monitor carefully, and stop CYLTEZO if infection becomes serious.
• Invasive fungal infections: For patients who develop a systemic illness on CYLTEZO, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic.
•Malignancies: Incidence of malignancies was greater in adalimumabtreated patients than in controls.
•Anaphylaxis or serious hypersensitivity reactions may occur.
•Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop CYLTEZO and begin anti-viral therapy.
•Demyelinating disease: Exacerbation or new onset, may occur.
•Cytopenias, pancytopenia: Advise patients to seek immediate medical attention if symptoms develop, and consider stopping CYLTEZO.
•Heart failure: Worsening or new onset, may occur.
•Lupus-like syndrome: Stop CYLTEZO if syndrome develops.